Brian O Mahony/X
Sep 13, 2025, 13:34
Brian O Mahony on 5-Year Roctavian Gene Therapy Data from BIC2025
Brian O Mahony, CEO of Irish Haemophilia Society, Former President of WFH and EHC, shared a post on X:
“Nugent BIC2025 presents 5 year data on valoctocogene roxaparvovec (Roctavian) GENE R-8 1 trial.
128 of 134 participants completed the trial. Using chromogenic assay at 5 years, mean FVIII 13.7, median 6.2 IU/dl 1/3”
Stay informed with Hemostasis Today.
-
Nov 8, 2025, 05:31Phenotyping of Human Platelets by Daisie Yates
-
Nov 8, 2025, 04:35Inaugural Women In Hematology US Focus Meeting 2025 Officially Commenced
-
Nov 7, 2025, 06:59Stephen Cornelissen is Celebrating an Extraordinary Milestone at Australian Red Cross Lifeblood
-
Nov 7, 2025, 06:56Reza Shojaei on Leadership in the Blood and Plasma Sector
-
Nov 7, 2025, 06:52Rachel Margolis-Goodman Announces Groundbreaking Expension of Versiti Blood Research Institute
-
Nov 7, 2025, 06:46What’s New in HIT from THANZ Webinar Series
-
Nov 7, 2025, 03:30Abdallah Othman About Cardiac Vasculature
-
Nov 7, 2025, 03:29Aabha Divya: Thrilled to Share Our Latest Publication in Annals of Thoracic Surgery Short Reports!
-
Nov 7, 2025, 03:28Shantel Holcomb: Boston Scientific is Investing in Innovative Solutions to Improve Outcomes for Patients With CAD